Streetbeat News

Products Services

TNXP

Tonix Pharmaceuticals has been granted a European Union patent for its intranasal potentiated oxytocin (TNX-1900) for pain treatment. The patent is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:02 am

GOOG

META

NVDA

SFTBF

Masayoshi Son, CEO of Softbank Group Corp, emphasized the importance of artificial general intelligence (AGI) during the company's annual event, predicting that AGI will surpass human intelligence within a decade. Son's advocacy comes amid a global race to harness AI's potential, led by tech giants like Meta Platforms Inc and Alphabet Inc. Son also revealed his daily interactions with GPT-4, an advanced AI model. SoftBank is preparing to re-enter tech investments, with a shift from a $43.9 billion investment in FY 2021 to a more modest $4 billion in the last fiscal year.

Portfolio Pulse from Anusuya Lahiri

October 04, 2023 | 11:01 am

META

MSFT

Meta Platforms Inc.'s Facebook Messenger's AI stickers feature is generating problematic content due to lack of filters. The feature, announced at the Meta Connect event in Sept. 2023, uses Llama 2 and Emu technologies to turn text prompts into stickers. However, it has been found to accept inappropriate prompts, generating potentially harmful content. Meta plans to roll out this feature to Instagram, Messenger, WhatsApp, and Facebook users. Microsoft Corp.-backed OpenAI's ChatGPT and Bing Chat's alternative persona Sydney have strict rules in place for safe AI development.

Portfolio Pulse from Rounak Jain

October 04, 2023 | 10:57 am

AZN

AstraZeneca's Forxiga has met its primary endpoint in the T2NOW Phase III trial, showing significant reduction in A1C, a marker of average blood sugar, for patients compared with placebo. The drug demonstrated clinically meaningful improvements in glycemia for children and adolescents with type 2 diabetes. The safety results were consistent with those in adults.

Portfolio Pulse from Charles Gross

October 04, 2023 | 10:54 am

ETON

Eton Pharmaceuticals has announced the acquisition of an FDA-approved ultra-rare disease product, Nitisinone, used for the treatment of hereditary tyrosinemia type 1 (HT-1). The disease affects less than 500 patients in the United States.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:52 am

STLA

WBX

Wallbox has announced a collaboration with Free2move eSolutions, a joint venture with Stellantis, to support Stellantis' dealerships in Canada with their electrification goals. The first stage of the collaboration will involve offering Supernova 180, a DC fast-charger capable of charging at up to 180kW.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:39 am

KRTX

Karuna Therapeutics will present new secondary efficacy, safety, tolerability, and pooled cognition data from its EMERGENT program evaluating KarXT (Xanomeline-trospium) in schizophrenia at the European College of Neuropsychopharmacology Congress.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:37 am

PHGE

BiomX has completed patient dosing in part 2 of the Phase 1b/2a study evaluating BX004 for the treatment of chronic pulmonary infections in patients with cystic fibrosis.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:36 am

VIAV

Viavi Solutions Inc. has launched NITRO Wireless, a cloud intelligence and automation solution designed to accelerate 5G and 6G networks. The new product is expected to enhance the company's portfolio and strengthen its position in the market.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:31 am

JOBY

Joby Aviation, Inc. (NYSE:JOBY) has expanded its flight test program to include flying with a pilot on board the aircraft. This is a critical step towards the company's goal of developing electric vertical take-off and landing (eVTOL) aircraft for commercial passenger service.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:06 am